On April 2, 2024 Imugene Limited (ASX: IMU), a clinical stage immuno-Oncology company, reported that its CF33-hNIS (VAXINIA) technology has been selected for a short oral presentation during the Basic Science Research Seminar Abstract Session at 12:15 pm on Thursday April 18th at the 2024 Cholangiocarcinoma Foundation Annual Conference (Press release, Imugene, APR 2, 2024, https://mcusercontent.com/e38c43331936a9627acb6427c/files/aac555dc-2479-31cc-7372-6973c7c0c6c8/Imugene_to_present_at_2024_Cholangiocarcinoma_Conference.01.pdf [SID1234641709]). Imugene will also be presenting a poster during the poster session.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment of cholangiocarcinoma and biliary tract malignancies,’ concludes that CF33-hNIS monotherapy may be an effective and safe treatment option for GI malignancies, including cholangiocarcinoma, a rare disease with an unmet medical need.
The Cholangiocarcinoma Foundation Annual Conference is dedicated to advancing the understanding and treatment of cholangiocarcinoma (bile duct cancer). The 2024 edition, marking the 11th annual conference, is scheduled for 17-19 April 2024 at the Salt Palace Convention Center in Salt Lake City, Utah. This conference brings together a wide array of participants, including medical professionals, researchers, patients, and caregivers, creating a unique platform for sharing the latest advancements in research, clinical trials, and patient care.
Cholangiocarcinoma is a rare and aggressive form of cancer that occurs in the bile ducts, which are the slender tubes that carry the digestive fluid bile from the liver to the small intestine. Early detection is challenging, and because of its aggressiveness, the prognosis for cholangiocarcinoma can be poor, making research and advancements in treatment essential.